Fig. 6
IgG78-DM1 could alleviate liver fibrosis in a therapeutic treatment model. A Schematic experimental design for the establishment and treatment of CCl4-induced mice. B Representative images of Masson staining, Sirius red staining, and IHC staining for α-SMA. C, D Quantification of the Masson and Sirius red positive area in B. E Ishak score of the liver tissues. F Hepatic hydroxyproline content after treatment. G Serum levels of ALT after treatment (n = 5 in B–G). H Western blotting showing the protein levels of α-SMA, collagen I and CD248 in the liver tissues. I qRT-PCR to show the mRNA levels of Cd248 and fibrosis-related genes (Acta2, Col1a1, Tgfbr1 and Pdgfrα) in the liver tissues (n = 3 in H–I). DM1 Mertansine, IHC immunohistochemistry, ALT alanine aminotransferase, α-SMA alpha smooth muscle actin, qRT-PCR quantitative real-time reverse transcription polymerase chain reaction